7k fewer students clear NEET in Gujarat, cut-offs likely to be lowered
This outcome is expected to trigger a significant downward adjustment in merit cut-offs, benefiting a broader range of aspirants eyeing MBBS, BDS, ayurveda, and homeopathy courses.
The stage is now set for the admission process, poised to begin in early July.
Last year, 57,232 students from Gujarat qualified in NEET, while this year, only 50,040 cleared the exam. Notably, in 2024, 16 students scored perfect 720 marks, but in 2025, no student achieved a full score.
According to medical admission sources, last year's last admission at BJ Medical College closed at 699 marks. This year, even the top scorer across India secured less than that, indicating that merit ranks will significantly drop across all medical colleges.
Currently, Gujarat has a total of 16,246 NEET-based seats: 6,958 in MBBS, 1,255 in BDS, 3,473 in ayurveda, and 4,560 in homeopathy. In addition, paramedical courses offer over 50,000 seats.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
5 Books Warren Buffett Wants You to Read In 2025
Blinkist: Warren Buffett's Reading List
Undo
Combining both, there are more than 70,000 seats available, meaning that most qualifying students are likely to get admission in at least one NEET or paramedical course.
The admission committee is preparing to begin the admission process in the first week of July. Officials mentioned that once all candidate data is received by the end of June, a detailed schedule will be announced.
Experts suggest that students who scored lower marks in NEET this year should explore opportunities not just in MBBS but also in BDS, ayurveda, and homeopathy. Moreover, approvals for three new medical colleges may add 300 more MBBS seats, along with expected increases in Ayush course seats.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
6 minutes ago
- Mint
Lilly's Zepbound faces a potential weight-loss rival. It's made by a Chinese biotech
A new late stage trial of a promising weight loss drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to US biopharma. A Chinese-developed weight loss shot looked almost as good as Eli Lilly's megablockbuster Zepbound in late-stage trial results rolled out Tuesday morning, in one more sign of the impending disruption that the booming Chinese biotech industry could bring to U.S. biopharma. The Jiangsu, China-based company Hengrui Pharma and its privately held U.S. partner Kailera Therapeutics said early Tuesday that patients lost an average of 18% of their weight over 48 weeks on Hengrui's drug, HRS9531. Using a statistical measure that only takes into account patients who completed the trial, their average weight loss was 19%. That's still not quite as good as Zepbound, which led to 21% weight loss in a late-stage trial. But the Zepbound trial was longer, and Hengrui and Kailera say that patients were still losing weight when the Hengrui trial ended. What's more, the latest Hengrui trial didn't study HRS9531 at its highest dose level. Hengrui plans to seek regulatory approval for the shot in China only 'as soon as possible" based on the new results. The drug won't pose a threat to Lilly anytime soon, if ever. But Kailera, the U.S. company that licensed the rights to HRS9531 outside of China, thinks they may be able to show it works better than Zepbound in their own trials, which have yet to start, and which are aimed at getting global approvals for the drug. 'Today's treatments are pretty much capped at about 20%" weight loss, said Kailera's chief commercial officer, Jamie Coleman, in an interview Tuesday with Barron's. 'Our goal is to maximize that efficacy, go beyond that." Even if Kailera eventually does show that HRS9531 can help patients lose more weight than Zepbound, the drug is years from U.S. approval, and would likely launch later than retatrutide, a follow-up medicine from Lilly that already works better than Zepbound. Lilly's hold on the weight loss market seems secure at least until the end of the decade, if not longer. Still, the promising data on HRS9531 is a hint at the challenges that Chinese biotech is increasingly posing for U.S. biopharma. As Barron's reported in June, U.S. drugmakers have spent tens of billions of dollars in recent months acquiring rights to experimental medicines invented by Chinese companies, in a sign of the growing quality and efficiency of the Chinese biotech sector. HRS9531 is one of a big group of Chinese-developed weight loss assets licensed by U.S. companies. Merck licensed an oral GLP-1 for $112 million up front in December of last year from Hansoh Pharma, and Regeneron licensed a GLP-1/GIP from the same company in June for $80 million up front. AstraZeneca, Lilly, and Novo Nordisk also have similar deals with other companies. It all adds complexity for investors trying to forecast the shape of the obesity market over the long term. And it's a potential threat to the U.S. biotech ecosystem, which relies on big pharma cash going to U.S. biotechs to fund development of new drugs. HRS9531, which Kailera calls KAI-9531, is very similar to Lilly's Zepbound: Both are dual GLP-1/GIP receptor agonists, and both are injectable peptides. In an earlier trial, also conducted by Hengrui, patients on a higher dose of HRS9531 lost 22.8% of their weight after 36 weeks. 'Generally speaking, what we've seen out of China so far, this data looks very similar to tirzepatide," said Coleman, using Zepbound's chemical name. 'We can go to higher doses without trading off tolerability, and we'll study it longer." Though the latest study was a Phase 3 trial, it only enrolled 567 patients, far fewer than would be needed in a U.S. Phase 3. Kailera launched in October with $400 million in private funding. It owns the rights outside of China to four Hengrui drugs including HRS9531. The question for Kailera is what the market would be for a drug that may be similar or a bit better than Zepbound, and how the biotech could ramp up manufacturing. Making significant quantities of the drug has been a challenge for Lilly, which has invested many billions of dollars in expanding its manufacturing capacity. Coleman, who was vice president, U.S. brand leader for Zepbound at Lilly before coming to Kailera, said that Kailera is already talking to contract manufacturers, and that more contract manufacturing capacity is available because Lilly and its competitor Novo Nordisk have brought much of their manufacturing in-house. 'We intend to focus and compete where weight loss matters the most, and where there are unmet needs in the market," Coleman said. 'There's a high level of unmet need in people that need to lose more than what tirzepatide today is providing. And there are very few molecules that are really set up to deliver higher efficacy, especially with a mechanism that is well-known, well-understood, and a tolerability profile that's pretty well accepted." Write to Josh Nathan-Kazis at
Time of India
17 minutes ago
- Time of India
How amla helps control diabetes naturally: Know its benefits and how to add it to your diet
Amla, also known as Indian gooseberry, is a powerful superfood long used in Ayurvedic medicine. Today, it's gaining popularity for its potential to help manage diabetes naturally. Rich in vitamin C, antioxidants, and bioactive plant compounds, Amla supports blood sugar regulation and improves insulin sensitivity. Studies suggest that Amla may reduce post-meal blood sugar spikes, promote better glucose metabolism, and lower inflammation, a key factor in diabetes-related complications. Its high antioxidant content also helps protect against oxidative stress, which is common in people with type 2 diabetes. Whether consumed as Amla juice, powder, or supplements, this fruit can be a valuable addition to a diabetes management plan when used under medical guidance. Top 5 benefits of amlas for diabetes 1. Helps regulate blood sugar levels Amla has been shown to stimulate insulin secretion, improve glucose uptake, and enhance insulin sensitivity, making it a natural remedy for controlling high blood sugar levels. Its ability to help balance blood glucose makes it especially valuable for people with type 2 diabetes. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Struggling With Belly Fat? Try This at Home Home Fitness Hack Shop Now Undo 2. Packed with antioxidants Amla is one of the richest sources of vitamin C and other antioxidants. These compounds help fight oxidative stress and inflammation, two common issues in individuals with diabetes that can worsen insulin resistance and increase the risk of complications. 3. Improves insulin sensitivity The polyphenols and tannins in Amla help slow the absorption of carbohydrates, reducing postprandial (after-meal) blood sugar spikes. This leads to improved insulin function and better overall blood sugar control. 4. Supports heart health Diabetes significantly increases the risk of heart disease. Amla may help by lowering LDL (bad) cholesterol, reducing triglycerides, and increasing HDL (good) cholesterol. Including Amla in a diabetes-friendly diet can support both metabolic and cardiovascular health. 5. May prevent diabetes complications Thanks to its anti-inflammatory and antioxidant properties, Amla may help protect against diabetes-related complications like nerve damage (neuropathy), kidney disease (nephropathy), and eye problems (retinopathy). How amla works in diabetes management Amla's anti-diabetic effects are primarily due to its rich nutritional and phytochemical profile: Vitamin C: Reduces inflammation and oxidative damage in diabetic patients. Polyphenols and tannins: Slow carbohydrate digestion and sugar absorption. Natural enzyme inhibitors: Help reduce the breakdown of starches and sugars in the digestive system. Insulin sensitisation: Enhances how the body uses insulin to move glucose into cells How to add amla to your diet for diabetes management You can easily add Amla to your diabetes management plan through the following methods: 1. Amla juice Take 30–50 ml daily, diluted with water. Best consumed on an empty stomach for maximum benefit. 2. Amla powder Add 1 teaspoon to smoothies, warm water, yoghurt, or herbal teas. It can also be mixed with honey or lemon for added taste. 3. Fresh amla Eat it raw, cooked, or added to Indian dishes, pickles, and chutneys. One raw Amla a day can offer substantial health benefits. 4. Amla supplements Available in capsules or tablets. Always consult a doctor or nutritionist before using supplements for diabetes. Precautions when using amla for diabetes While Amla is generally safe and natural, here are a few things to keep in mind: Consult your doctor: Before adding Amla or any supplement to your diabetes diet plan, especially if you're on medication. Monitor blood sugar: Amla may lower your glucose levels, so keep track to avoid hypoglycemia. Medication interaction: Amla may interact with insulin or oral diabetic medications — don't make changes without medical advice. Also read | Food and drinks to avoid if you have diabetes
Time of India
18 minutes ago
- Time of India
CBSE's new ‘Oil Board' mandate aims to curb rising student obesity and promote healthier living
In a move that places student well-being at the heart of school life, the Central Board of Secondary Education ( CBSE ) has issued a fresh circular encouraging all affiliated schools to adopt 'Oil Boards' as a visual cue to promote healthier dietary choices. 'Oil Boards' refer to visual displays such as posters or digital screens placed in common areas that warn against excessive consumption of unhealthy fats and oils. The circulate dated July 15, 2025, comes as a natural extension of CBSE's earlier 'Sugar Boards' initiative, reinforcing its stance on preventive health through awareness and behavioural change among students. At the core of this initiative is a growing concern around obesity in India, especially among children and adolescents. Data from NFHS-5 (2019–21) shows that one in five adults in urban India is overweight or obese. More worryingly, a recent study published in The Lancet projects that the number of overweight and obese adults in India will more than double by 2050. Lifestyle-induced health conditions, once confined to adults, are now steadily impacting teenagers due to excessive consumption of high-fat and sugary foods combined with reduced physical activity. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Pernas e tornozelos inchados? Descubra o que pode ajudar a drenar agora aartedoherbalismo Undo Schools to lead the way In response, CBSE is urging schools to turn students into stakeholders in their own health journeys. Schools are now encouraged to: • Install 'Oil Boards' across cafeterias, hallways, and common rooms to initiate conversations among students about the impact of high-fat diets. • Print health-conscious messages on school diaries, notebooks, and folders, offering daily prompts for students to rethink their food and activity habits. • Make healthier food options more accessible on campus, focusing on fresh fruits, vegetables, and low-fat alternatives, while simultaneously curbing the sale of packaged snacks and sugary drinks. • Promote physical activity by organising 'movement breaks,' encouraging stair usage, and creating walkable routes within the school premises. Importantly, the initiative invites students to be creators, not just consumers. Schools are advised to integrate Oil Board design into class projects, encouraging students to research, conceptualise, and create health communication content, a valuable exercise in both life skills and creative expression. The circular also directs schools to refer to relevant educational content available on FSSAI's official YouTube channel. Institutions can further connect with FSSAI at iec@ for resources or guidance. This initiative underscores a growing consensus that the classroom can no longer remain isolated from the larger questions of student health and lifestyle. With visual nudges, peer engagement, and school-wide involvement, CBSE hopes to instill lasting habits in students, ones that extend beyond academics and into the fundamentals of well-being. For today's generation navigating academic pressure, digital fatigue, and changing food patterns, CBSE's move is a reminder that learning to make healthier choices is as vital as learning to solve equations. Explore the complete CBSE circular on this initiative here . TOI Education is on WhatsApp now. Follow us here . Ready to navigate global policies? Secure your overseas future. Get expert guidance now!
